A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Metadata only so far. Questions are answered only with quotes from this document. Source: ctgov, ctgov, retrieved 2026-11-04.
Stopped earlyPI left NIH.
Record metadata
- Phase
- Phase 2
- Status
- Withdrawn
- Start
- 2025-09-09
- End
- 2025-09-09
- Enrollment
- 0
- Sites
- 1
- Sponsor class
- NIH
Not in the data yet: a trial card. Cards (population, design, endpoints, result direction, each tied to a quote) arrive with the knowledge layer’s card lane. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s licensed passages, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
No passages are loaded for this document yet.